(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide
- Product Name
- (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide
- CAS No.
- 1492952-76-7
- Chemical Name
- (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide
- Synonyms
- Asciminib;ABL-001;EOS-61420;L1F3R18W77;ABL001;ABL-001;UNII-L1F3R18W77;asciminib free base;ABL-001 (ASCIMINIB);Asciminib (ABL-001);ABL-001; AB -001; ABL001; ASCIMINIB; ASCIMINIB FREE BASE;
- CBNumber
- CB23133462
- Molecular Formula
- C20H18ClF2N5O3
- Formula Weight
- 449.84
- MOL File
- 1492952-76-7.mol
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Property
- Boiling point:
- 631.7±55.0 °C(Predicted)
- Density
- 1.518±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:93.0(Max Conc. mg/mL);206.74(Max Conc. mM)
Ethanol:90.0(Max Conc. mg/mL);200.07(Max Conc. mM) - form
- A crystalline solid
- pka
- 10.81±0.70(Predicted)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 26126
- Product name
- Asciminib
- Packaging
- 1mg
- Price
- $62
- Updated
- 2024/03/01
- Product number
- 26126
- Product name
- Asciminib
- Packaging
- 10mg
- Price
- $477
- Updated
- 2024/03/01
- Product number
- 26126
- Product name
- Asciminib
- Packaging
- 5mg
- Price
- $254
- Updated
- 2024/03/01
- Product number
- 0090DW
- Product name
- Asciminib
- Packaging
- 5mg
- Price
- $380
- Updated
- 2021/12/16
- Product number
- CS-7655
- Product name
- Asciminib
- Purity
- 99.78%
- Packaging
- 5mg
- Price
- $155
- Updated
- 2021/12/16
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Chemical Properties,Usage,Production
Description
Asciminib is the first-in-class Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) inhibitor, which was granted accelerated approval in 2021 for patients with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs), and for adult patients with Ph+ CML in chronic phase with the T315I mutation. Asciminib binds to a myristoyl site of the BCR-ABL1 protein and locks the protein into an inactive conformation through a mechanism distinct from those of all other orthosteric TKIs such as imatinib, thus overcoming drug resistance arising from ATPbinding site mutations. Asciminib mimics the function of the myristoylated N-terminus of ABL1 and restores the natural autoinhibition of the ABL1b protein.
Uses
Asciminib comprises ABL kinase inhibitors and/or SLC7A11 inhibitors for the treatment of cancer and central nervous system (CNS) disorders.
General Description
Class: non-receptor tyrosine kinase
Treatment: CML
Elimination half-life = 14.2 h
Protein binding = 97%
target
BCR-ABL1